Evidence map›Paper›PMID 40743786›Full record

ArticleClinical imaging2025

The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients.

Nadia Shah, Ashkan Eighaei Sedeh, Caitlin Deffler, Thomas S C Ng, Nathaniel Mercaldo, Xin Gao, Umar Mahmood, Pedram Heidari, Shadi A Esfahani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nadia ShahDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: nkshah@mgh.harvard.edu.
Ashkan Eighaei SedehDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: ashy19923@gmail.com.
Caitlin DefflerDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: cdeffler@mgh.harvard.edu.
Thomas S C NgDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: sheung.ng@mgh.harvard.edu.
Nathaniel MercaldoDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: nmercaldo@mgb.org.
Xin GaoDepartment of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: xgao4@mgb.org.
Umar MahmoodDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: umahmood@mgh.harvard.edu.
Pedram HeidariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: heidari.pedram@mgh.harvard.edu.
Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America. Electronic address: Esfahani.shadi@mgh.harvard.edu.

Funding

Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA259626
6 · The paper itself

Abstract

purposeThis study evaluates the ability of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) to distinguish between benign and malignant solitary bone lesions (SBLs) in prostate cancer (PCa) patients in correlation with standard imaging and clinical features.

methods18F-piflufolastat and 68Ga-gozetotide PSMA PET/CT imaging reports of 1480 PCa patients from September 2021 to February 2023 were retrospectively reviewed. SBLs were classified as benign, malignant, or indeterminate based on imaging reports. Indeterminate SBLs were followed up over six months for reclassification. Comparative analyses, including Wilcoxon rank sum and chi-squared tests, assessed differences in standardized uptake values on PET, prostate-specific antigen (PSA) levels, and lesion locations.

results208 of 1480 (14 %) PSMA PET/CT scans reported an SBL. 106/208 (51 %) SBLs were malignant, 56/208 (27 %) benign, and 46/208 (22 %) indeterminate. Compared to benign lesions, malignant SBLs had a significantly higher SUV

conclusionLocation, SUV

Indexed as

Bone NeoplasmsPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overDiagnosis, DifferentialGlutamate Carboxypeptidase IIHumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesGlutamate Carboxypeptidase IIRadiopharmaceuticalsMetastasisPET/CTProstate cancerProstate-specific membrane antigenSolitary bone lesions

Identifiers

PMID40743786
PMCPMC13045874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.